“We … are currently evaluating resource allocation, including pipeline prioritization and a workforce reorganization,” CFO Kimi Iguchi said in an Aug. 7 investor call.
The drug, Zurzuvae (zuranolone), is the first FDA-approved drug to treat postpartum depression, but Sage and its partner Biogen have not yet announced the list price.
Sage did not immediately reply to Becker’s request for details on how many jobs might be affected, and no WARN notices have been filed in states with Sage locations, Massachusetts and North Carolina.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
